High cost oncology drugs without proof of added benefit are burdening health systems
BMJ
.
2024 Feb 29:384:q511.
doi: 10.1136/bmj.q511.
Authors
Francine Brinkhuis
1
,
Wim G Goettsch
1
2
,
Aukje K Mantel-Teeuwisse
1
,
Lourens T Bloem
1
Affiliations
1
Division of pharmacoepidemiology and clinical pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands.
2
National Health Care Institute, Diemen, Netherlands.
PMID:
38423553
DOI:
10.1136/bmj.q511
No abstract available
Publication types
Editorial
MeSH terms
Cost-Benefit Analysis
Drug Costs*
Humans
Medical Oncology*